To determine whether VZV ORF10 is required for viral replication in vitro, we constructed two VZV mutants which were unable to express ORF10. One mutant had a stop codon after the 61st codon of the ORF10 gene, and the other mutant was deleted for all but the last five codons of the gene. Both VZV mutants grew in cell culture to titers similar to that of the parental virus. To determine whether HSV-1 VP16 alters the growth of VZV, we constructed a VZV mutant in which VP16 was inserted in place of ORF10. Using immune electron microscopy, we found that HSV-1 VP16 was present in the tegument of the recombinant VZV virions. The VZV VP16 substitution mutant produced smaller plaques and grew to a lower titer than parental virus. Thus, VZV ORF1O is not required for growth of the virus in vitro, and substitution of HSV-1 VP16 for VZV ORF10 impairs the growth of VZV.
Varicella-zoster virus (VZV) is the causative agent of chickenpox and herpes zoster. VZV encodes five genes, open reading frame 4 (ORF4) (12, 19, 26) , ORF10 (21) , ORF61 (20, 25, 27) , ORF62 (12, 27) , and ORF63 (13) , that regulate viral gene expression in transient expression assays.
VZV ORF10 protein is the homolog of herpes simplex virus type 1 (HSV-1) VP16 (also known as alpha trans-inducing factor or Vmw65). The two genes have similar locations within their respective viral genomes. The predicted amino acid sequences of VZV ORF10 and HSV-1 VP16 are highly homologous, except that ORF10 lacks the acidic carboxy terminus of VP16 (9, 16, 21) .
VZV ORF10, like its HSV-1 homolog VP16, transactivates VZV ORF62 and HSV-1 immediate-early (IE) genes in transient expression assays; however, ORF10 protein does not transactivate the putative IE VZV ORF4 and ORF61 genes. In transient expression assays using the same promoter to drive VZV ORF10 and HSV-1 VP16, VP16 is over three times more active than ORF10 in transactivating the VZV ORF62 promoter (21) . The transcriptional activation domain of HSV-1 VP16 is located at the carboxy terminus of the protein (29) , in a region which has apparently been deleted from VZV ORF10. In contrast, the transcriptional activation domain of VZV ORF10 is located at the amino terminus of the protein (22) . VZV ORF10 enhances the infectivity of transfected VZV virion DNA, but to a much less extent than enhancement of infectivity of transfected HSV-1 DNA by VP16 (23) . VZV ORF10 is able to complement an HSV-1 VP16 mutant which lacks the transactivating function of VP16 (21) . VZV ORF10 and HSV-1 VP16 are both components of their respective virion teguments (1, 14) .
HSV-1 VP16 is a phosphoprotein that is expressed during the late phase of virus replication. HSV-1 mutants that fail to express VP16 at elevated (1) or at normal (33) temperatures have been constructed. These mutant viruses are unable to replicate unless they are grown at the permissive temperature or are complemented by using a cell line that expresses VP16.
Since VZV ORF10 has many, but not all, of the properties of HSV-1 VP16, we determined whether ORF10 is essential for viral replication in vitro. Construction of VZV mutants with stop codons in ORF10 or deleted for ORF10 indicated that VZV ORF10 is not essential for VZV replication, and lack of the gene product did not reduce replication of VZV in vitro. In addition, we determined whether substitution of a more potent transactivator, VP16, for ORF10 would enhance the replication of VZV. Construction of VZV mutant in which VP16 is inserted in place of ORF10 resulted in a virus that grew less well than the parental VZV.
MATERMILS AND METHODS
Cells and viruses. Human melanoma (MeWo) cells were used for transfections and propagating virus. MeWo cells expressing VZV ORF10 (MlOR-15 [21] ) were propagated in minimal essential medium supplemented with 10% fetal bovine serum and 250 ,ug of G418 (Geneticin; Life Technologies, Inc./GIBCO, Grand Island, N.Y.) per ml. Recombinant VZV was derived from the attenuated Oka strain of VZV (31) . The malignant schwannoma cell line (ST88-14) was kindly provided by Cynthia Morton (28) .
Cosmids and plasmids. Cosmids VZV NotI A, Not I BD, MstII A, and Mst IIB contain the entire genome of the Oka strain of VZV ( Fig. 1) (5) . To produce a cosmid with a stop codon in ORF10, cosmid VZV NotI A was cut with Sse8387I (Takara Biochemicals, Berkeley, Calif.), and the 12.9-kb VZV fragment (VZV nucleotides 9780 to 22631 [9] ) was cloned into pUC19 to produce pUC-Sse (5) . A partial digest of pUC-SSe was performed with NheI, which cuts the plasmid at two sites (VZV nucleotides 12340 and 19208 [9] once by pulsed-field gel electrophoresis, and the DNA was blunted by using the large (Klenow) fragment of T4 DNA polymerase. A double-stranded oligonucleotide (TAGCTAG GCGCGCCTAGCTA) which contains stop codons in all three reading frames and an AscI restriction endonuclease site was inserted into the NheI site of pUC-Sse. Eschenichia coli was transformed with the ligated DNA, and colonies which contained plasmids in which the oligonucleotide had been inserted at VZV nucleotide 12340 were selected. The plasmid containing the oligonucleotide was sequenced to verify that the oligonucleotide had the correct sequence and was inserted at the correct site. The plasmid was then cut with Sse878I, and the large fragment containing the mutated DNA was inserted into cosmid VZV NotI A in place of the wild-type sequence. This cosmid, VZV NotI A-1OS, contains the ORF10 gene with stop codons inserted after the 61st codon of the gene (Fig. 1) . Two independent clones of VZV NotI A-1OS were selected. To construct a cosmid deleted for ORF10, a synthetic double-stranded oligonucleotide containing AvrII and NruI restriction endonuclease sites (AATTCCTAGGAGATCTT CGCGACTGCA) was cloned into the EcoRI-PstI site of pGEM2 (Promega Corporation). Plasmid pUC-Sse was cut with AvrII and NruI (which cut at VZV nucleotides 11725 and 14476), and the 2.75-kb VZV DNA fragment was cloned into the AvrII-NruI site of the modified pGEM2 plasmid to yield plasmid pGEM/AvrII-NruI. The latter plasmid was cut with PmlI, which cuts the plasmid at three sites (VZV nucleotides 12050, 12971, and 13370 [9] ). The large 4.3-kb fragment was ligated to itself and sequenced to verify that the expected DNA had been deleted. Two clones, one in which VZV nucleotides 12047 to 13374 had been deleted and another in which VZV nucleotides 12044 to 13374 had been deleted, were selected. Each clone was cut with AvrII and NrulI, and the mutated fragment was inserted into pUC-Sse in place of the wild-type AvrII-NruI fragment. The resulting plasmids were cut with Sse8781, and the mutated 11.5-kb fragments were inserted into the VZV NotI A cosmid in place of the wild-type sequence. These cosmids, VZV NotI A-1ODA and NotI A-1ODB, have a deletion beginning 113 or 116 nucleotides before the first codon of ORF10 and ending at codon 405 of ORF10 (Fig. 1) .
To construct a cosmid in which the ORF10 gene is replaced with the HSV-1 VP16 gene, we isolated a 2.15-kb BstBI-XhoI fragment containing HSV-1 VP16 and its promoter (HSV-1 nucleotides 103379 to 105530 [3, 16] ) from plasmid HSV-1 XbaI D (4). Plasmid pGEM/AvrII-NruI was cut with PmI1 (which cuts at VZV nucleotides 12050, 12971, and 13370 [9] ), and the large 4.3-kb fragment was ligated to the HSV-1 BstBI-XhoI fragment to produce plasmid pGEM-VP16. The latter plasmid was cut with AvrII and NruI, and the fragment containing the VZV and HSV-1 sequences was inserted into pUC-Sse in place of the wild-type AvrII-NruI fragment. The resulting plasmid was cut with Sse8781, and the mutated 11.5-kb fragment was inserted into the VZV NotI A cosmid in place of the wild-type sequence to yield cosmid VZV NotI A-1OD/VP16. Plasmid pCMV62, which contains the VZV transactivator ORF62 driven by the human cytomegalovirus IE promoter, was described previously (27) .
Transfections. Immunoblotting with rabbit antibody to VZV ORF10 was performed as described previously (5) . Detection of VZV glycoprotein I (gpl) was performed by using a murine monoclonal antibody (Chemicon, Temecula, Calif.) and an antimouse antibody coupled to horseradish peroxidase. Detection of HSV-1 VP16 was performed by using a rabbit antiserum to the carboxy portion of VP16 (32) Immune electron microscopy. MeWo cell monolayers infected with VZV or HSV-1 were fixed with 1% glutaraldehyde and 0.2% picric acid, and the cells were scraped and pelleted. The cell pellets were dehydrated with ethanol, embedded in plastic resin, sectioned, and placed onto nickel grids. The sections were incubated with a rabbit antibody to HSV-1 VP16, followed by colloidal gold-labeled goat anti-rabbit antibody, and visualized by electron microscopy.
Preparation of cell-free VZV. Cell-free VZV was prepared by scraping flasks of VZV-infected MlOR-15 cells, pelleting the cells, and sonicating the cells three times in SPGC medium (phosphate-buffered saline with 10% fetal bovine serum, 5% sucrose, and 0.1% sodium glutamate [30] Fig. 2A and B) . Digestion of VZV ROkal3S with EcoRI andAscI cut the 14-kb EcoRI C band of VZV DNA into two smaller bands of 12 and 2 kb (arrow in Fig.   2C ) due to the AscI site in the oligonucleotide inserted into the viral genome.
To verify that cells infected with ROkalOS did not express full-length ORF10 protein, cell extracts were prepared and immunoblotted with a rabbit antibody to ORF10. Cells infected with parental recombinant VZV (ROka) expressed a 50-kDa ORF10 protein, while uninfected cells or cells infected with VZV ROkalOS did not express ORF10 (Fig. 3A) . A different aliquot of cell extract was also immunoblotted and probed with a monoclonal antibody to VZV gpI. Cells infected with ROkalOS produced VZV gpl (Fig. 3B) , indicating that the absence of expression of ORF10 was not due to lack of VZV gene expression.
Since VZV ROkalOS may express a truncated form of ORF10 that contains the first 61 amino acids of the protein, we constructed another mutant in which nearly the entire ORF10 gene is deleted to ensure that ORF10 is not essential for Fig. 2A) and EcoRI (Fig. 2B) Fig. 2 because of similar sizes of other fragments.) Digestion of VZV ROkalODA and ROkalODB with XbaI, however, results in reduction in size of the 8.2-kb XbaI F fragment of VZV DNA by 1.3 kb, yielding a new band of 6.9 kb (arrows in Fig. 2D ) due to the deletion in ORF10.
Western blotting (immunoblotting) of protein extracts from VZV ROkalODA and ROkalODB confirmed that cells infected with the mutant viruses do not express ORF10 (Fig.  3A) , while another aliquot from the same protein extract showed that the cells expressed VZV gpl (Fig. 3B) .
Deletion of VZV ORF1O does not reduce the level of VZV 0RF62 protein in virus-infected cells. VZV ORF10 transactivates the ORF62 promoter in transient expression assays (21) . To determine whether cells containing virus deleted for ORF10 had reduced levels of VZV ORF62 protein, we infected cells with parental (ROka) and ORF10-deleted (ROkalOD) VZV and performed immunoprecipitations with a monoclonal antibody directed against VZV ORF62 (Fig. 4A) (Fig. 5A) . Similarly, VZV with a stop codon in ORF10 grew to titers similar to that of the parental virus in melanoma cells (7) .
VZV RNA has been detected in satellite cells in human ganglia (8) . Since Schwann cells are the peripheral nervous system equivalent of satellite cells, we infected schwannoma cells with parental and mutant VZV. VZV deleted for ORF10 grew to titers similar to that of the parental virus in schwannoma cells (Fig. SB) . Therefore, deletion of ORF10 does not inhibit the growth of VZV in cell culture.
VZV in which ORF1O is replaced with HSV-1 VP16 can replicate in cell culture. HSV-1 VP16 is a potent transactivator that enhances the infectivity of VZV and HSV-1 virion DNA (23) . To determine if expression of HSV-1 VP16 enhances the growth of VZV in cell culture, we constructed VZV in which ORF10 was replaced by HSV-1 VP16 (Fig. 1) . Cosmids VZV NotI A-1OD/VP16A and VZV NotI A-1OD/VP16B are deleted for all of ORF10, except for the last five amino acids, and contain the HSV-1 VP16 gene driven by its endogenous promoter. The two cosmids differ only in the orientation of the cassette containing the VP16 gene and its promoter.
B. Cosmid VZV NotI A-1OD/VP16A or VZV NotI A-1OD/ VP16B and the other three parental cosmids were transfected into MeWo cells. The four parental cosmids were also transfected into cells on the same day. Five days after transfection, the cells were split into new flasks, and 9 days after transfection, at a time when plaques were visible in cells transfected with the four parental cosmids, no cytopathic effects were noted in cells transfected with the VZV NotI A-1OD/VP16 cosmids. The cells were treated with trypsin and passaged into larger flasks; 4 days later (13 days after transfection), cytopathic effects typical of VZV were noted in cells transfected with the VZV NotI A-1OD/VP16 cosmids.
The resulting viruses, VZV ROkalOD/VP16A and ROkalOD/ VP16B, were propagated in MeWo cells, and viral DNA was prepared for Southern blotting. Digestion of ROka, ROkalOD/ VP16A, and ROkalOD/VP16B DNAs with BamHI (Fig. 6A) and EcoRI (Fig. 6B) showed similar patterns of bands when hybridized with a probe to all four VZV cosmids. (The 2.35-and 1.35-kb BamHI fragments are replaced with a 4.5-kb band which overlaps with other BamHI fragments, and the 14.3-kb EcoRI C fragment increases to 15.1 kb as a result of deletion of ORF10 and insertion of VP16.) Hybridization with a probe to HSV-1 VP16 indicated that VP16 was inserted into the EcoRI C fragment of VZV (Fig. 6C) .
Western blotting of protein extracts from VZV ROkalOD/ VP16A and ROkalOD/VP16B confirmed that cells infected with these viruses expressed HSV-1 VP16, while cells infected with the parental (ROka) virus did not express VP16 (Fig. 7) .
VZV in which ORF10 is replaced with HSV-1 VP16 contains VP16 in the virion tegument. Cells infected with ROkalOD/ VP16, ROkalOD, and HSV-1 strain KOS were fixed, sectioned, incubated with a rabbit anti-VP16 antibody followed by colloidal gold-labeled goat anti-rabbit antibody, and examined by electron microscopy. VP16 was present in the tegument of 78% of extracellular ROkalOD/VP16 virions. VP16 on was present in HSV-1 virions but not ROkalOD virions (Fig.  8) .
Similar numbers of viral particles were present in cells infected with ROka, ROkalOD, and ROkalODIVP16, and there was no apparent difference in virion assembly or the proportion of nucleocapsids containing dense or empty cores (7).
Substitution of VZV ORF1O by HSV-1 VP16 does not afect the level of VZV 0RF62 proteinein virus-infected cells. HSV-1 VP16 transactivates the VZV 0RF62 promoter in transient expression assays (21) . To determine whether cells infected with virus containing HSV-1 VP16 had differences in the level of VZV 0RF62, we infected cells with parental (ROka) and VPl6-containing (ROkalOD/VPl6) VZV and assayed the level of VZV 0RF62 by immunoprecipitation with a monoclonal antibody directed against ORF62 (Fig. 9A) . Cells infected with ROka aa, ROkalOD/VP16 expressed similar A amounts of ORF62 protein. Immunoprecipitations performed with a monoclonal antibody to VZV gpl indicated that the similar levels of ORF62 were associated with similar degrees of VZV infection (Fig. 9B) .
Substitution of VZV ORF10 by HSV-1 VP16 impairs the growth of the virus in cell culture. The plaque sizes of cells infected with VZV ROka and VZV ROkalOD/VP16 were compared by infecting melanoma cells and staining the monolayers 1 week after infection. Cells infected with VZV ROka 1OD/VP16A or VZV ROka1OD/VP16B produced smaller plaques than cells infected with the parental virus (Fig. 10) . The mean size of plaques for cells infected with VZV ROka was 0.69 ± 0.17 mm (standard deviation SD), while the mean size of plaques for cells infected with VZV ROkalOD/VP16A was 0.44 ± 0.13 mm (SD), and that for cells infected with VZV ROkalOD/VP16B was 0.50 ± 0.22 mm (SD). The mean plaque size produced by infection of cells with the two viruses in which VZV ORF10 was substituted with HSV-1 VP16 was significantly smaller than the mean plaque size for cells infected with parental virus (P < 0.01, Tukey multiple comparison test).
To determine whether substitution of VZV ORF10 by HSV-1 VP16 alters the growth of the virus in cell culture, we inoculated melanoma cells with cells infected with VZV ROka, ROkalOD/VP16A, and ROkalOD/VP16B and measured the production of virus at days 0, 1, 2, 3, 4, and 5 after infection. VZV ROka1OD/VP16A and ROka1OD/VP16B grew to lower titers than the parental ROka virus (Fig. 11) . Thus, the plaque size and titration experiments together indicate that substitution of VZV ORF10 by HSV-1 VP16 reduces the growth of the virus in vitro.
The potent transactivating ability of VP16 may allow HSV-1 to replicate in a wide variety of host cells (10 VZV containing VP16 did not allow the virus to grow more efficiently.
DISCUSSION
We have shown that VZV ORF10 is not essential for replication of the virus in cell culture. Previous studies have shown that VZV-encoded enzymes (5, 11, 15) and a VZV glycoprotein (6) are not essential for growth of VZV in vitro. In this study, we have shown that a tegument protein is not required for growth of VZV in vitro.
The HSV-1 homolog of VZV ORF10, VP16, is essential for growth of HSV-1 in cell culture. Deletion of VP16 abolishes the ability of HSV-1 to grow in cell culture, unless the mutant is grown in a VP16-expressing cell line. Electron microscopic studies of the VP16 deletion mutant indicate that the virus has a defect in capsid maturation and virion assembly (33) . Insertion of an oligonucleotide into the VP16 gene that abolishes the ability of VP16 to transactivate IE genes and to form complexes with cell proteins and the TAATGARAT element results in a mutant HSV-1 that still grows in cell culture (2).
ROka
ROkalOD/VP16 Since VP16 is known to be present in the viral tegument, these observations suggest that the structural (tegument) domain of VP16 may be essential, but that the transactivation and certain protein binding functions may not essential for growth in vitro. VZV ORF10, like HSV-1 VP16, is a structural protein present in the virion (14) . However, since VZV ORF10 is not essential for VZV replication, while HSV-1 VP16 is essential, our results imply that ORF10 has structural properties in the VZV virion different from those of VP16 in the HSV-1 virion. Indeed, immune electron microscopy of cells infected with parental VZV or VZV deleted for ORF10 showed no apparent differences in virion assembly or capsid maturation.
Cells infected with VZV deleted for ORF10 expressed amounts of VZV ORF62 similar to those expressed by cells infected with parental virus. Previous studies from our laboratory indicated that ORF10 can transactivate the ORF62 promoter in transient expression assays (21 VZV deleted for ORF10 grew to a titer similar to that of the parental VZV. A VP16 insertion mutant that lacks transactivating activity grows well at a high multiplicity of infection (MOI) but poorly at a low MOI (2). While we were unable to obtain sufficient cell-free virus to compare the growth of parental and ORF10-deleted VZV at different MOIs, infection of about 106 cells with about 100 PFU of cell-associated ORF10-deleted virus showed no difference in growth compared with parental virus. The VP16 insertion mutant has reduced virulence when injected into mice (2) . Therefore, the ORF10 deletion mutant that we constructed, which lacks this transactivating VZV protein, might also have a less virulent phenotype in vivo.
In humans, VZV is latent in dorsal root ganglia and viral RNA has been found in satellite cells (8, 18) . Schwann cells have a function in the peripheral nervous system similar to that of satellite cells in the ganglia, and the two types of cells have similar structural features (24) . Since a human satellite cell line does not exist at present, we tested the growth of our mutant in a schwannoma cell line. VZV deleted for ORF10 grew to a titer similar to that of the parental virus in schwannoma cells. The mutant virus also grew in a human neuroblastoma cell line (7) . Thus, ORF10 does not play an essential role for VZV replication in transformed neural or nonneural cells in vitro.
Levels of ORF62 protein were similar in cells infected with VZV in which VP16 had been substituted for ORF10 and cells infected with parental VZV. VP16 is known to interact with cellular proteins and TAATGARAT sequences in promoters of HSV-1 IE genes. VZV ORF62 is the only IE VZV gene that contains a TAATGARAT sequence in its promoter region (17) and therefore might be the only VZV gene that could respond to VP16. In accord with this prediction, previous studies from our laboratory showed that VP16 transactivates the ORF62 promoter but not the promoters for ORF4 and ORF61 (21) . Thus, the observation that cells infected with parental VZV, VZV deleted for ORF10, or VZV containing VP16 all express similar levels of the potent transactivating ORF62 protein indicates that VZV has evolved a strategy to optimize levels of ORF62 protein without the need for an additional transactivator such as VP16.
VZV in which VP16 had been substituted for ORF10 grew to a lower titer and produced smaller plaques than parental VZV in vitro. VP16 was found in the tegument of the recombinant VZV, and there was no apparent difference noted in virion assembly by immune electron microscopy. However, the presence of VP16 in the tegument may have interfered with a different step of virus infection (e.g., uncoating of viral DNA), or expression of VP16 may have altered the orderly cascade of VZV gene expression impairing the growth of the virus in cell culture.
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